Product Name: Recombinant Human LGALS3 (C-6His)
Catalog #: PHH0704

Summary

Name	Galectin-3/LGALS3
Purity	Greater than 95% as determined by reducing SDS-PAGE
Endotoxin level	<1 EU/μg as determined by LAL test.
Construction	Recombinant Human Galectin-3 is produced by our Mammalian expression system and the target gene encoding Ala2-Ile250 is expressed with a 6His tag at the C-terminus.
Accession #	AAH53667.1
Host	Human Cells
Species	Human
Predicted Molecular Mass	27.2 KDa
Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, 3mM DTT, pH 7.4.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Stability&Storage	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Background

Product Name: Recombinant Human LGALS3 (C-6His)
Catalog #: PHH0704

Alternative Names	Galectin-3; Gal-3; 35 kDa Lectin; Carbohydrate-Binding Protein 35; CBP 35; Galactose-Specific Lectin 3; Galactoside-Binding Protein; GALBP; IgE-Binding Protein; L-31; Laminin-Binding Protein; Lectin L-29; Mac-2 Antigen; LGALS3; MAC2
Background	Galectin-3(LGALS3) is also known as Galactose-specific lectin 3, Mac-2 antigen, Carbohydrate-binding protein 35, Laminin-binding protein and Galactoside-binding protein. LGALS3 is highly expressed in early stages of papillary carcinoma, and lowly during tumor progression. LGALS3 is probably forms homo- or heterodimers and secreted by a non-classical secretory pathway and associates with the cell surface. LGALS3 plays an important role during the acquisition of vasculogenic mimicry and angiogenic properties. LGLAS3 takes part in an immune regulator to inhibit T-cell immune responses and promote tumor growth, as a result providing a new mechanism for tumor immune tolerance.

Note

For Research Use Only , Not for Diagnostic Use.